LEGISLATION/R&D/LASER THERAPY: How the two sides of healthcare reform affect biophotonics

The landmark healthcare legislation Congress passed in March 2010 promises to boost research and innovation, but paying for those programs may mean medical device manufacturers take a hit to their bottom lines (see sidebar "Paying for reform"). The more than 2000-page "Patient Protection and Affordable Care Act" offers new sources of funding for researchers and small- to medium-sized R&D firms. Among the provisions to assist R&D is a tax credit for companies that develop technologies or techniques to diagnose, treat, or prevent disease. Other initiatives support comparative effectiveness research and give the green light to the Cures Acceleration Network (CAN), a program to rapidly translate innovative laboratory research to clinical settings.

Helping small R&D

The Qualifying Therapeutic Discovery Project tax credit, championed by Sen. Robert Menendez (D-NJ), is aimed at companies with fewer than 250 employees. These businesses can claim up to 50% of R&D expenses related to:

  • Treating or preventing diseases/conditions by conducting preclinical activities, clinical trials, and clinical studies, or carrying out research protocols, to secure approval by the U.S. Food and Drug Administration;
  • Diagnosing diseases/conditions or developing diagnostics based on the molecular activity associated with a disease/condition that would help guide therapeutic decisions; or
  • Developing a product, process, or technology to further the delivery or administration of therapeutics.

 

Making reference to molecular diagnostics in the legislation suggests Congress is getting the message about the new paradigm of personalized medicine and bodes well for optical technologies.

The tax credit also permits companies to apply for a grant in lieu of the credit. This option could be beneficial to early-stage companies that may not have taxable income that can be offset by a credit. The program is expected to get underway by the end of May 2010.

Comparing treatments

Over the last five years comparative effectiveness research has been hotly debated. The recent stimulus funding awarded to the National Institutes of Health (NIH) included provisions to identify which procedures, technologies, and services provide the best patient outcomes. The healthcare reform legislation now establishes the Patient-Centered Outcomes Research Institute (PCORI) to examine an array of services and procedures to determine which ones work best at preventing, diagnosing, and treating disease.

The PCORI will develop a national research agenda based on a number of factors including disease prevalence and the potential for new evidence that might improve patient health. Expert advisory panels drawn from academia, government, and industry will assist in clinical trial design and supply technical support in the case of device studies. By 2015 PCORI's budget is expected to top out at $600 million a year.

Jennifer K. Barton, director, division of biomedical engineering at the University of Arizona, sees inclusion of comparative effectiveness in the healthcare legislation as a boon for laser medicine. "Especially in emerging areas, the healthcare bill will motivate large-scale serious studies comparing different approaches." She cites a recent pilot study in which photobiomodulation, a technique that uses low-level light to moderate pain, stimulate nerves, and heal wounds, was found to be less costly and had fewer side effects than drug therapy.

Turning discoveries into therapies

The Cures Acceleration Network (CAN), first introduced by Sen. Arlen Specter (D-PA) in 2009, could turn out to be a bonus for researchers and advocacy groups. CAN will award grants through NIH to biotech companies, universities, and patient advocacy groups to bridge the gap between basic scientific discoveries and their application as clinical therapies.

Through CAN, the federal government will pursue more high-risk, high-reward research and should be able to move that research to clinical trials and patients more quickly than through traditional mechanisms. CAN projects will also get fast-track treatment through the FDA approval process. The legislation calls for an oversight board that includes key stakeholders from medicine, medical instrumentation, basic research, pharmaceuticals, patient advocacy organizations, and agencies outside of NIH. To support CAN, Congress has authorized $500 million, with a ceiling for individual project awards set at $15 million.

Now that the debate and political posturing has quieted, the work of implementing healthcare reform begins. The legislation describes very specific timeframes for initiating programs and in some cases eliminating them. The reforms discussed in this article do have the potential to improve patient care. However, as with many big-ticket programs (think Superconducting Supercollider) that Congress authorizes, over time the costs are often too great to sustain and the benefits are never realized.

–Susan M. Reiss


Paying for reform

 

More Brand Name Current Issue Articles
More Brand Name Archives Issue Articles

POST A COMMENT

Related Articles

Ophthalmology laser maker Iridex secures large tender from Government of Zambia

Ophthalmology laser maker Iridex secures large tender from Government of Zambia

Iridex (NASDAQ: IRIX) has been awarded a competitive tender for more than $350,000 in ophthalmology laser equipment by the government of Zambia.

Worldwide photomedicine market to reach $754M by 2019, says BCC Research

Worldwide photomedicine market to reach $754M by 2019, says BCC Research

A new report from BCC Research forecasts that the global photomedicine market is expected to reach $754 million by 2019, registering a compound annual growth rate (CAGR) of 4.1 percent for the 2014...
A hypertrophic burn scar two months following three fractional CO2 laser treatments

Mature scars with erythema benefit from fractional CO2 laser treatment

A new study conducted by a team of researchers, using a fractional CO2 laser, resulted in clinical improvement of erythema (redness of the skin).

University of Utah electrical and computer engineering associate professor Rajesh Menon holds up a piece of silicon that has been etched with microscopic pillars and holes to create a polarized filter that can allow more light to pass through than conventional polarizers, which is useful for low-light microscopy

New polarizing filter allows more light for use in low-light microscopy

Engineers have developed a novel polarizing filter that allows in more light than typical polarizers, which block enormous amounts of light, wasting energy and making it more difficult to image in ...
BLOGS

Single-molecule tracking promises discoveries, cures

New ways of imaging individual proteins and lipids will ultimately change science and medicine.

Growth in lasers for medicine

At the Lasers and Photonics Marketplace Seminar during SPIE Photonics West 2015, analyst Allen No...

Also at BiOS 2015

Although the BiOS Expo closes on Sunday, February 8, 2015, the conferences of the Biomedical Opti...

Most Popular Articles


CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2014. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS